XingImaging Selected to Lead Imaging Operations for Landmark Alzheimer's Tau Platform Phase II Trial
核心洞察
XingImaging (搜索) has been chosen as the Imaging Core Lab for the NIH-supported Alzheimer's Tau Platform Phase II trial, which will enroll up to 750 participants across 78 U.S. clinical sites.
The groundbreaking multi-arm study will simultaneously evaluate multiple tau-directed therapies in preclinical and prodromal Alzheimer's disease using quantitative tau PET as the primary endpoint.
The trial represents one of the most ambitious imaging-driven interventional studies in Alzheimer's research, combining tau and amyloid PET biomarkers for comprehensive pathology assessment.
XingImaging (搜索) has been selected as the Imaging Core Lab for the Alzheimer's Tau Platform (ATP), a groundbreaking, multi-arm, randomized Phase II clinical trial designed to simultaneously investigate multiple tau-directed therapeutic candidates in preclinical and prodromal Alzheimer's disease. The study is supported by the National Institutes of Health under Grant R01AG078457 and represents one of the most ambitious imaging-driven interventional studies ever undertaken in Alzheimer's research.
The ATP trial will enroll up to 750 participants across approximately 78 clinical sites in the United States. As the Imaging Core Lab, XingImaging (搜索) will oversee all PET imaging operations across the study, which evaluates whether tau-directed therapies—alone or in combination with an anti-amyloid therapy—can reduce pathological tau accumulation as measured by tau PET, the study's primary imaging endpoint.
Quantitative PET Imaging at Trial's Core
The ATP trial's primary objective is to determine whether at least one tau-targeted therapy produces a greater reduction in brain tau deposition—measured by tau PET SUVR—than anti-amyloid therapy alone. The trial incorporates both quantitative tau and amyloid PET imaging, with the inclusion of amyloid PET providing an additional molecular baseline and longitudinal readout, enabling a comprehensive evaluation of Alzheimer's pathology.
"Quantitative tau PET is at the heart of the ATP trial, and we are delighted to serve as the Imaging Core Lab for a study of such scientific and clinical significance," said Roger Gunn, PhD, Chief Scientific Officer at XingImaging (搜索). "The combination of tau and amyloid PET biomarkers offers unprecedented insight into therapeutic impact, disease progression, and patient stratification."
Target Population and Study Design
The ATP trial focuses on individuals aged 50–80 with late preclinical or early prodromal Alzheimer's disease, confirmed through plasma biomarkers, elevated tau and amyloid PET. This patient population represents a critical window for therapeutic intervention before significant cognitive decline occurs.
"The ATP trial represents a new generation of Alzheimer's disease therapeutic studies—ones that rely on sensitive, quantitative biomarkers to understand treatment effects with unprecedented precision," said Keith Johnson, MD, Co-Principal Investigator of the ATP Trial. "Tau PET imaging provides a direct window into the core pathology driving cognitive decline, while amyloid PET allows detailed characterization of amyloid burden."
Advancing Precision Medicine Approach
The selection of XingImaging (搜索) reflects the growing importance of high-quality molecular imaging in Alzheimer's therapeutic development. The company's integrated PET imaging capabilities position it to deliver the precision and consistency required for a trial of this scale and complexity.
"This is exactly the type of platform where high-quality, quantitative imaging can accelerate therapeutic discovery," said Gilles Tamagnan, PhD, CEO of XingImaging (搜索). "We are committed to supporting the ATP consortium by delivering imaging science, operational excellence, and advanced analytics capable of powering next-generation therapeutic development for Alzheimer's disease."
XingImaging (搜索) operates from New Haven, Connecticut, with over 24,000 square feet of research and operational space and more than 60 scientific, technical, and clinical staff members. The organization includes dedicated divisions for Clinical Operations, Chemistry, Imaging Sciences, Regulatory Affairs, Quality Assurance, Imaging & Data Management Services, IT, and Business Operations, enabling full end-to-end imaging support for early- and late-stage therapeutic development programs.